1016232-58-8

Upstream product

• 145354-28-5 (20R)-des-A,B-8β-(benzoyloxy)-23,24-dinorcholane-22-ol 
• 64190-52-9 (8S,20S)-de-A,B-20-(hydroxymethyl)pregnan-8-ol 
• 66774-70-7 (8S,20S)-des-A,B-8-benzoyloxy-20-(hydroxymethyl)-pregnane 
• 66774-71-8 Benzoic acid (1R,3aR,4S,7aR)-7a-methyl-1-((S)-1-methyl-2-oxo-ethyl)-octahydro-inden-4-yl ester 
• 50-14-6 Calciferol 
• 115527-12-3 (20R)-des-A,B-8β-(benzoyloxy)-23,24-dinorcholan-22-al 
• 1016232-57-7 (8S,20S)-des-A,B-8-benzoyloxy-20-[(4'S)-hydroxy-pent-(1'E)-en-yl]-pregnane 
• 69739-34-0 t-butyldimethylsiyl triflate 

Relevant academic research and scientific papers

26-Desmethyl-2-methylene-22-ene-19-nor-1α,25-dihydroxyvitamin D 3 compounds selectively active on intestine

Six new analogs of 2-methylene-19-nor-1α,25-dihydroxyvitamin D 3, 6-7 and 8a,b-9a,b, have been synthesized. All compounds are characterized by a trans double bond located in the side chain between C-22 and C-23. While compounds 6 and 7 possess

2-Methylene-(20S,25S)-19,27-Dinor-(22E)-Vitamin D Analogs

This invention discloses 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity